

Supplementary Table 1: Clinico-pathologic characteristics by race in GRID validation cohort, n = 792

Baseline Characteristics	AAM (n = 243)	WHITE (n = 549)	p value
ETS Status			
Negative	186 (76.5)	309 (56.3)	< 0.001
Positive	57 (23.5)	240 (43.7)	
Pathology Gleason Score			
≤ 3+3	20 (2.5)	61 (11.1)	< 0.001
3+4	152 (62.5)	202 (36.8)	
4+3	39 (16.0)	106 (19.3)	
≥ 8	32 (13.2)	178 (32.4)	
Unknown	0	2 (0.4)	
iPSA (ng/ml)			
≤ 6	101 (41.6)	133 (24.2)	< 0.001
> 6 - 10	59 (24.3)	141 (25.7)	
> 10 - 20	38 (15.6)	94 (17.1)	
> 20	20 (8.2)	72 (13.1)	
Unknown	25 (3.2)	109 (19.8)	
Surgical Margins			
Present	114 (46.9)	252 (45.9)	0.7
Absent	129 (53.1)	297 (54.1)	
Extracapsular Extension			
Yes	54 (6.8)	248 (45.2)	< 0.001
No	189 (77.8)	298 (54.3)	
Unknown	0	3 (0.5)	
Lymph Node Invasion			
Yes	2 (0.8)	59 (10.7)	< 0.001
No	240 (98.8)	469 (85.4)	
Unknown	1 (0.4)	21 (3.8)	
Seminal Vesical Invasion			
Yes	25 (10.3)	150 (27.3)	< 0.001
No	218 (89.7)	399 (72.7)	
CAPRA-S Score			
0 - 2	77 (31.7)	43 (7.8)	< 0.001
3 - 5	91 (37.4)	208 (37.9)	
6 - 12	50 (20.6)	184 (33.5)	
Unknown	25 (10.3)	114 (20.8)	
Age at Diagnosis (Years)			
≤ 50	15 (6.2)	37 (6.7)	0.05
> 50 - 65	128 (52.7)	334 (60.8)	
> 65	100 (41.1)	178 (32.4)	
Abbreviations: AAM, African American; iPSA, Preoperative Prostate Specific Antigen; CAPRA-S, Cancer of the Prostate Risk Assessment Surgical			